BofA analyst Alec Stranahan lowered the firm’s price target on Perspective Therapeutics (CATX) to $6 from $7 and keeps a Neutral rating on the shares. The Q1 report reinforced the progress of the radiopharmaceutical pipeline with “a slew of updates” expected in late-2026, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)
- Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances
- Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update
- Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data
- Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET